Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?

Autor:	Greuter MJ; Department of Epidemiology & Biostatistics, Decision Modeling Center, Amsterdam UMC - Vrije Universiteit Amsterdam, The Netherlands., Carvalho B; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wit M; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dekker E; Department of Gastroenterology, Amsterdam UMC - Academic Medical Center, Amsterdam, The Netherlands., Spaander MC; Department of Gastroenterology & Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Engeland MV; Department of Pathology, GROW - School for Oncology & Developmental Biology, Maastricht, The Netherlands., Coupé VM; Department of Epidemiology & Biostatistics, Decision Modeling Center, Amsterdam UMC - Vrije Universiteit Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Journal of comparative effectiveness research [J Comp Eff Res] 2020 Jun; Vol. 9 (8), pp. 563-571. Date of Electronic Publication: 2020 May 28.
DOI:	10.2217/cer-2019-0130
Abstrakt:	Aim: To assess the potential of biomarker triage testing (BM-TT) in the Dutch colorectal cancer (CRC) screening program. Materials & methods: Using the Adenoma and Serrated pathway to Colorectal CAncer model, we simulated fecal immunochemical test (FIT) 47 -screening and various FIT plus BM-TT screening scenarios in which only individuals with both a positive FIT and BM-TT are referred to colonoscopy. Results: Adding a low polyp sensitivity BM-TT to FIT-screening reduced colonoscopy burden (89-100%) while increasing CRC mortality (27-41%) compared with FIT 47 -screening only. The FIT plus high polyp sensitivity BM-TT scenarios also decreased colonoscopy burden (71-89%) while hardly affecting CRC mortality (FIT 47 0-4% increase, FIT 15 2-7% decrease). Conclusion: Adding a BM-TT to FIT-screening considerably reduces colonoscopy burden, but could also decrease screening effectiveness. Combining FIT 15 with a high polyp sensitivity BM-TT seems most promising.
Databáze:	MEDLINE
Externí odkaz: